Stockholders’ (Deficit) Equity (Details) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Apr. 06, 2020 |
Jul. 31, 2021 |
Feb. 17, 2021 |
Sep. 30, 2021 |
Dec. 31, 2020 |
Sep. 30, 2018 |
Jul. 01, 2017 |
|
| Stockholders’ (Deficit) Equity (Details) [Line Items] | |||||||
| Common stock, shares authorized | 200,000,000 | 200,000,000 | |||||
| Common stock par value (in Dollars per share) | $ 0.001 | $ 0.001 | |||||
| Shares issued | 105,897 | 149,762 | 62,181 | ||||
| Exchange for cash price, per unit (in Dollars per share) | $ 5 | $ 4.21 | $ 4.21 | $ 0.013 | |||
| Warrants term | 5 years | 5 years | |||||
| Exercise price (in Dollars per share) | $ 6 | $ 6 | |||||
| Proceeds of warrants (in Dollars) | $ 7,500 | ||||||
| Converted shares | 736,773 | ||||||
| Convertible debt shares granted | 184,193 | ||||||
| Description of consulting exercised | employees and consultants exercised a total of 383,721 stock options and the Company received $119,000 in proceeds. A portion of these options were exercised early (prior to vesting), and as of September 30, 2021, 100,388 of the options remained unvested. Proceeds received related to the unvested options of $68,000 at September 30, 2021 were recorded in accrued liabilities on the accompanying balance sheets and will be reclassified to equity as vesting occurs, provided the employees and consultants continue to provide services to the Company. The vested portion of the exercises was 283,335 shares at September 30, 2021. | ||||||
| Issued shares | 348,837 | 1,767,442 | 33,263 | 33,263 | |||
| Investors exchange of shares | 24,627 | ||||||
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 | |||||
| Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | |||||
| Warrants [Member] | |||||||
| Stockholders’ (Deficit) Equity (Details) [Line Items] | |||||||
| Common stock price, per share (in Dollars per share) | $ 8 | ||||||
| Shares issued | 4,000,000 | ||||||
| Purchase of additional warrants shares | 600,000 | ||||||
| Common Stock [Member] | |||||||
| Stockholders’ (Deficit) Equity (Details) [Line Items] | |||||||
| Common stock price, per share (in Dollars per share) | $ 4.99 | ||||||
| Shares issued | 5,000,000 | ||||||
| Spectrum Pharmaceuticals, Inc. [Member] | |||||||
| Stockholders’ (Deficit) Equity (Details) [Line Items] | |||||||
| Shares issued | 438,374 | 313,663 | |||||